Orforglipron

Oral non-peptide GLP-1 receptor agonist — pill-based, no fasting window required.

Typical dose range: 12–45 mg

Frequency: Daily

Route: Oral

Half-life: ~24 h

Evidence level: Phase 3

Overview

Lilly's oral small-molecule GLP-1. Unlike Rybelsus it doesn't require empty-stomach dosing, which is the headline advantage if approved.